

Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)



Salvador Pérez-Galera,^{a,b,aa} Jose M. Bravo-Ferrer,^{a,aa} María Paniagua,^{a,z} Tomislav Kostyaney,^{c,d} Marlieke E. A. de Kraker,^e Jan Feifel,^f Jesús Sojo-Dorado,^a Joost Schotsman,^g Rafael Cantón,^{h,i} George L. Daikos,^j Biljana Carevic,^k Gorana Dragovac,^l Lionel K. Tan,^m Lul Raka,ⁿ Adriana Hristea,^o Pierluigi Viale,^p Murat Akova,^q Jose María Reguera,^r Lucía Valiente de Santis,^r Julián Torre-Cisneros,^{i,s} Ángela Cano,^s Emmanuel Roilides,^t Lili Radulovic,^u Cenk Kirakli,^v Evelyn Shaw,^{i,w} Matthew E. Falagas,^{x,y} Vicente Pintado,^{h,i} Herman Goossens,^c Marc J. Bonten,^f Belén Gutiérrez-Gutiérrez,^{a,i,ab} and Jesús Rodríguez-Baño,^{a,i,ab,*} the COMBACTE-CARE-EURECA Team^{ac}



^aUnidad de Enfermedades y Microbiología, Hospital Universitario Virgen Macarena and Departamento de Medicina, Universidad de Sevilla/Instituto de Biomedicina de Sevilla/CSIC, Seville, Spain

^bServicio de Medicina Interna, Hospital Universitario Virgen Macarena, Seville, Spain

^cVaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium

^dLaboratoire National de Santé, Luxembourg, Luxembourg

^eInfection Control Program, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

^fInstitute of Statistics, Ulm University, Ulm, Germany

^gDepartment of Medical Microbiology and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands

^hServicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain

ⁱCIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain

^jLaiko General Hospital, National and Kapodistrian University of Athens, Athens, Greece

^kDepartment of Hospital Epidemiology, Clinical Center of Serbia, Belgrade, Serbia

^lFaculty of Medicine and Institute of Public Health of Vojvodina, University of Novi Sad, Novi Sad, Serbia

^mGSK, Brentford, UK

ⁿUniversity of Prishtina "Hasan Prishtina" and National Institute of Public Health of Kosovo, Prishtina, Kosovo

^oUniversity of Medicine and Pharmacy 'Carol Davila', Bucharest, Romania

^pMalattie Infettive, Policlinico Sant'Orsola, Bologna, Italy

^qDepartment of Infectious Diseases and Clinical Microbiology, Hacettepe University Faculty of Medicine, Sıhhiye, Ankara, Turkey

^rServicio de Enfermedades Infecciosas, Hospital Regional Universitario de Málaga, Ibima, Málaga, Spain

^sServicio de Enfermedades Infecciosas Hospital Universitario Reina Sofía/Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)/Universidad de Córdoba (Departamento de Ciencias Médicas y Quirúrgicas), Córdoba, Spain

^tHippokratia General Hospital of Thessaloniki, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece

^uZvezdara University Medical Center, Belgrade, Serbia

^vDr. Suat Seren Chest Diseases and Surgery Training Hospital, Izmir, Turkey

^wDepartment of Infectious Diseases, Hospital Universitari de Bellvitge, Institut d'Investigacions Biomèdiques de Bellvitge/IDIBELL, Barcelona, Spain

^xHenry Dunant Hospital Center, Athens, Greece

^yMetropolitan General Hospital, Athens, Greece

Summary

Background Data on risk factors for carbapenem-resistant Enterobacterales (CRE) with wider applicability are needed to inform preventive measures and efficient design of randomised trials.

Methods An international matched case-control-control study was performed in 50 hospitals with high CRE incidence from March 2016 to November 2018 to investigate different aspects of infections caused by CRE (NCT02709408).

eClinicalMedicine
2023;57: 101871

Published Online 27

February 2023

<https://doi.org/10.1016/j.eclinm.2023.101871>

*Corresponding author. Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Avda Dr Fedriani 3, Seville 41009, Spain.

E-mail address: jesusrb@us.es (J. Rodríguez-Baño).

^zPresent affiliation: Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen del Rocío, Sevilla, Spain.

^{aa}Salvador Pérez-Galera and Jose M. Bravo-Ferrer contributed equally as first authors.

^{ab}Belén Gutiérrez-Gutiérrez and Jesús Rodríguez-Baño contributed equally as senior authors.

^{ac}Members of the COMBACTE-CARE-EURECA team are listed in a [Supplementary Annex](#).

Cases were patients with complicated urinary tract infection (cUTI), complicated intraabdominal (cIAI), pneumonia or bacteraemia from other sources (BSI-OS) due to CRE; control groups were patients with infection caused by carbapenem-susceptible Enterobacterales (CSE), and by non-infected patients, respectively. Matching criteria included type of infection for CSE group, ward and duration of hospital admission. Conditional logistic regression was used to identify risk factors.

Findings Overall, 235 CRE case patients, 235 CSE controls and 705 non-infected controls were included. The CRE infections were cUTI (133, 56.7%), pneumonia (44, 18.7%), cIAI and BSI-OS (29, 12.3% each). Carbapenemase genes were found in 228 isolates: OXA-48/like, 112 (47.6%), KPC, 84 (35.7%), and metallo- β -lactamases, 44 (18.7%); 13 produced two. The risk factors for CRE infection in both type of controls were (adjusted OR for CSE controls; 95% CI; p value) previous colonisation/infection by CRE (6.94; 2.74–15.53; <0.001), urinary catheter (1.78; 1.03–3.07; 0.038) and exposure to broad spectrum antibiotics, as categorical (2.20; 1.25–3.88; 0.006) and time-dependent (1.04 per day; 1.00–1.07; 0.014); chronic renal failure (2.81; 1.40–5.64; 0.004) and admission from home (0.44; 0.23–0.85; 0.014) were significant only for CSE controls. Subgroup analyses provided similar results.

Interpretation The main risk factors for CRE infections in hospitals with high incidence included previous colonization, urinary catheter and exposure to broad spectrum antibiotics.

Funding The study was funded by the Innovative Medicines Initiative Joint Undertaking (<https://www.imi.europa.eu/>) under Grant Agreement No. 115620 (COMBACTE-CARE).

Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Keywords: Antimicrobial resistance; Carbapenem-resistant Enterobacterales; Risk factors; KPC; OXA; Metallo-beta-lactamases

Research in context

Evidence before this study

We search PubMed and Scopus until June 2022 combining the terms carbapenem-resistant or carbapenemase-producing, enterobacteriaceae or enterobacterales *Klebsiella*, and risk factors or predisposing factors, and used systematic reviews and meta-analysis as filters. We found 4 systematic reviews of risk factors, and reviewed the primary articles included in them. The literature review of studies investigating the risk factors for carbapenem-resistant Enterobacterales (CRE) provided results for which their extrapolation is limited because they were performed mostly in one or few sites or wards, included only *Klebsiella pneumoniae* infections, and/or used patients with susceptible organisms as the only control group.

Added value of this study

The design of EURECA allows a better generalizability of its results as it was performed in 50 hospitals from 10 countries in Southern Europe and included two control groups (patients

with carbapenem-susceptible Enterobacterales [CSE] and patients without infection), which were matched according to site of infection (for CSE), ward and previous hospital stay. This design controlled the confounding effect of the local epidemiology situation at each site and the time-dependent bias for the exposures. Also, the use of two control groups allowed to identify the variables increasing the probability of CRE infection, and to quantify their relative impact among patients with Enterobacterales infection and admitted patients, respectively.

Implications of all the available evidence

The risk factors found can be easily collected and be considered for deciding empirical treatment according to the local epidemiology and for the efficient design of future randomised trials in order to maximise the population at risk of CRE. Also, the results may help in designing preventive measures focused on patients at high risk.

Introduction

Antimicrobial resistance is recognised as one of the most important public health problems.¹ Among resistant bacteria, the dramatic increase in the rate of carbapenem-resistant Enterobacterales (CRE) during the last decade is among the most worrisome phenomena

because the alternatives available for their treatment are extremely limited; in fact, CRE are considered a priority for research in drug development by the World Health Organisation (WHO).² Infections caused by these bacteria are associated with worse outcomes, longer hospitalizations and higher costs compared to their

susceptible counterparts.^{2,3} The most frequent mechanism of resistance to carbapenems in Enterobacterales are production of class A (e.g., KPC enzymes), B (metallo- β -lactamases such as NDM or VIM, among others) and D carbapenemases (OXA-48 and OXA-48-like).⁴

Most previous studies investigating the risk factors for infections caused by CRE included limited number of patients, were performed in individual hospitals and some lack adequate control for key confounders,^{5–8} therefore jeopardizing the generalizability of their results. When trying to identify risk factors for infections caused by resistant bacteria, several aspects need to be considered, including the population under consideration, the group of patients used as reference, the variables investigated and how confounding is controlled both in the design and in the analysis.

The objective of this study was to investigate the risk factors for and profile of patients with infections caused by CRE in a case-control-control multinational study in countries with a high incidence of CRE, which can be useful for the selection of high risk populations for more efficient design of randomized trials, for developing preventive strategies and for considering empirical therapy. The study targeted the most frequent infections caused by CRE, and the design was based on specified epidemiological assumptions related to CRE epidemiology and pathways for the development of infection.

Methods

Study design, participants, sites and study period

The European Prospective Cohort Study on Enterobacteriaceae Showing Resistance to Carbapenems (EURECA) is a multinational study performed in 50 European hospitals from March 2016 to November 2018

to investigate different aspects of infections caused by CRE (NCT02709408).⁹ The 50 participating hospitals were located in ten European countries: Albania, Croatia, Greece, Italy, Kosovo, Montenegro, Romania, Serbia, Spain and Turkey. These sites were selected based on their rate of CRE infection, experience in clinical studies and laboratory capabilities. Participating sites included consecutive cases diagnosed with the target infections (complicated urinary tract infections [cUTI], complicated intraabdominal infections [cIAI], pneumonia and bloodstream infections from other sources [BSI-OS]) caused by CRE. The study protocol is available as [Supplementary Annex A](#).

For this analysis, a nested matched case-control study design was used, based on several pre-defined hypotheses and assumptions ([Table 1](#)). Patients included in the EURECA prospective CRE cohort were eligible as cases, and two control groups representing two different populations were chosen. The first control group included patients with infections caused by carbapenem-susceptible Enterobacteriaceae (CSE control group; one control per case); the comparison of CRE cases and CRE control represented the population of patients with infections due to Enterobacterales. The second control group included patients hospitalized without CRE infection (non-infected control group; three controls per case), and the comparison of CRE and non-infected patients represented the population of patients admitted to the hospitals. Patients in both control groups were matched to CRE cases for hospital ward and previous length of hospital stay, with an accepted difference of –3 days in the control groups (–7 days if previous stay for the case was >14 days to avoid time-dependent bias)¹⁰; CSE controls were also matched by type of infection ([Table 1](#)). CRE cases were prospectively

1. Time at risk (i.e., previous duration of hospitalization) and the colonization pressure (i.e., ward of admission) were considered obvious risk factors, which effect might cause an underestimation of the impact of other variables. Therefore, the study was designed using them as matching variables, and were planned to be described for the CRE cases in order to provide the information needed to understand the data. For the comparison between CRE and CSE controls, the type of infection (cUTI, cIAI, pneumonia or BSI-OS) were also to be used as matching variables.
2. The study was intended to be applicable to hospital with endemic transmission of CRE; therefore, it was to be performed in hospitals reporting a minimum number of CRE cases during the previous year.
3. The pathogenic relation between variables were not hypothesised as the intention was not to develop a pathogenic model. However, the exposure to variables was analysed in hierarchical models by grouping the variables by their hypothetical pathogenic action, including: variables associated with risk of CRE acquisition (“epidemiological variables”), variables associated with intrinsic features of the patients (“intrinsic variables”), variables associated with invasive procedures (“invasive procedures”; these might be associated with risk of acquisition but also with risk of developing a procedure-associated infection), and exposure to antibiotics.
4. Infection due to CRE is considered to happen after acquisition of CRE colonisation in most of the cases; therefore, epidemiological variables potentially associated with acquisition of CRE colonisation beyond time at risk and ward are considered, including: previous hospitalisation; being admitted from home as potentially protective, as opposed to being admitted from a long term-care facility or being transferred from another hospital; being an ambulatory or nosocomial contact of a patient colonised or infected with CRE; having travelled abroad; having had contact with pets or farm animals before admission; and having been detected previously as colonised or infected with CRE or other multidrug-resistant bacteria.
5. Intrinsic variables were considered constant throughout the exposure time; these included age, sex, ethnicity, and chronic underlying conditions.
6. Exposure to invasive procedures included central venous catheter, bladder catheter, mechanical ventilation, surgery, endoscopic procedures and renal replacement procedures; these were considered only until the day of infection by CRE or CSE, or the matched duration of admission in admitted controls.
7. Previous exposure to antibiotics during the previous 3 months was exploratory. Therefore, it was considered both as dichotomous variables (i.e., yes/no) and time-dependent variables (i.e., time of exposure to each antibiotic); the antibiotics were analysed independently and in groups according to families and spectrum of activity (see [Table 2](#)).
8. The microorganisms of interest for the study were carbapenem-resistant (regardless the mechanism of resistance) and carbapenemase-producing (regardless the MIC to carbapenems) Enterobacterales (this match the Center for Disease Control definition for CRE).

Table 1: Predefined hypothesis and assumptions for the design of the risk factors study.

detected in all sites by daily review of the microbiology reports. Once a CRE case was included, control patients fulfilling the above mentioned matching criteria were “prospectively” recruited at the same site, until the estimated sample size was reached.

STROBE recommendations for reporting results of observational studies were followed.¹¹

Variables, data collection and quality control

The variables collected are listed and defined in [Table 2](#); a full definition is provided in the study protocol ([Annex A](#)). The definition of timing for exposures was decided according to previous publications or the expected timeframe for their potential effect. The data were collected by local investigators in real time (i.e., while patients were admitted at hospital); all local teams at each participating site were trained remotely before the site was opened for recruitment for the study design, criteria, variables and data collection. The data were monitored remotely for missing information (i.e., any missing data prompted a query to local investigators to check if the data could be completed; unanswered queries were sent up to 3 times) and coherence by the central coordinating team at Hospital Universitario Virgen Macarena in Seville and country or region coordinators. All exposures were considered until “day 0”, which was the day when the first sample yielding CRE or CSE was obtained for the diagnosis of the infection of interest; for non-infected patients, it was the day from admission equivalent to day 0 for the correspondent CRE case.

Microbiological definitions and studies

The microorganisms of interest were carbapenem-resistant (according to EUCAST breakpoints)¹² and/or carbapenemase-producing (regardless of the minimum inhibitory concentration [MIC] to carbapenems) Enterobacterales ([Table 1](#)). For ease of understanding, we will refer to them as CRE. In order to detect most carbapenemase-producers, all Enterobacterales with MIC ≥ 1 mg/L (dilution methods) or ≤ 22 mm (disc-diffusion, 10 μ g disks) for meropenem or imipenem were considered as putative CRE. Identification and susceptibility testing were performed by local laboratories using standard microbiological techniques after training for procedures homogeneity; putative CRE isolates were also studied locally using the CARBA NP test. All CRE isolates were preserved at -20°C and sent to central laboratories where identification and susceptibility confirmation (Ramón y Cajal University Hospital, Madrid, Spain), and characterisation of carbapenemase genes by whole genome sequencing (Antwerp University, Belgium) were performed.

Statistical analyses

We targeted the inclusion of 248 CRE cases, distributed by type of infection according to previous studies^{13,14} as

follows: cUTI, $\approx 50\%$; pneumonia, $\approx 30\%$; and cIAI and BSI-OS, $\approx 10\%$ each, to be able to include at least 20 risk factors in a multivariate model. For each CRE case patient, one CSE and three admitted control patients were planned, in order to approximate the statistical power of full cohort data.¹⁵

Missing data were quantified ([Supplementary Annex B, Table S1](#)); the Little MCAR test was used to verify that missing data were at random, and multiple imputation was performed using the Markov chain Monte Carlo method. In order to characterize the impact of previous antibiotic use, we tested the effect of exposure to individual drugs or groups (both as dichotomous variables and as days of exposure), to drugs active only against gram positive bacteria, against anaerobic bacteria and to broad-spectrum anti-gram negative bacteria (including carbapenems, fluoroquinolones, piperacillin-tazobactam and oxymino- β -lactams). For duration of exposure to antibiotics, in addition to being considered as continuous variables, we used classification and regression tree (CART) analyses in order to identify thresholds for duration associated with increased risk.

For the analysis of risk factors, exposure to potential risk factors among CRE and CSE patients, and among CRE and non-infected controls was performed by hierarchical conditional logistic regression for matched data. To do so, the variables were classified into hierarchical groups ([Table 1](#)). A manual backward selection method of variables was used; the variables were kept in the models if their p value was < 0.1 . Despite being used as a matching variable and because a rank of days was tolerated (see above), previous hospital stay was included in all models. The predictive capacity of the multivariate models was evaluated by calculating the area under the receiver operating characteristics curve (AUROC) with 95% confidence interval (CI). The analyses were performed using IBM SPSS (version 26.0) and CART software 8.0 (Salford Systems).

Ethical approval

The study was approved by the Ethics Committee of the Hospital Universitario Virgen Macarena (FIS-ATB-2015-01). The need to obtain written informed consent was waived due to the observational and epidemiological nature of the study. Approval was also gained at the participating centres according to local requirements.

Role of funding

The funders had no role in the design, conduction of the study, decision to publish or writing of the article.

Results

During the study period, 732 patients with infection caused by CRE were included; of these, the first 235

	CRE group (n = 235) n (%)	CSE group (n = 235) n (%)	p	Non-infected group (n = 705) n (%)	p
Demographics and epidemiological context					
Age (years), median (IQR)	73 (62–82)	70 (59–79)	0.081	67 (53–77)	<0.001
Male sex	134 (57.0)	126 (53.6)	0.42	412 (58.4)	0.69
Caucasian ethnicity	231 (98.3)	229 (97.4)	0.42	690 (97.9)	0.63
Present admission from:					
Home	174 (74.0)	203 (86.4)	0.001	637 (90.4)	<0.001
Nursing home	9 (3.8)	9 (3.8)	1.0	9 (1.3)	0.015
Other long term-care facility	19 (8.1)	7 (3.0)	0.01	10 (1.4)	<0.001
Another acute care hospital	32 (13.6)	16 (6.8)	0.01	49 (7)	0.001
Previous acute care hospitalization (last 6 months)	150 (63.8)	104 (44.3)	<0.001	224 (31.8)	<0.001
Travel abroad (last 6 months)	4 (1.7)	3 (1.7)	0.56	35 (5.0)	0.037
Household/residency mates colonized/infected by CRE	15 (6.4)	11 (4.7)	0.46	6 (0.9)	<0.001
Other patient(s) colonized/infected by CRE in the same ward during admission	77 (32.8)	66 (28.1)	0.22	248 (35.2)	0.35
Healthcare worker or caregiver of dependant person	1 (0.4)	4 (1.7)	0.21	7 (1.0)	0.42
Usual contact with pets, last 6 months	33 (14.0)	32 (13.6)	0.88	110 (15.6)	0.42
Any contact with farm animals, last 6 months	1 (0.4)	5 (2.1)	0.14	16 (2.3)	0.092
Mean days of previous stay (SD)	9.2 (15.1)	7.4 (13.7)	<0.001	7.7 (10.4)	<0.001
Previous colonisation/infection by CRE ^a	50 (21.3)	8 (3.4)	<0.001	6 (0.9)	<0.001
Previous colonization/infection by other MDRO ^b	25 (10.6)	18 (7.7)	0.18	24 (3.4)	<0.001
Type of acquisition of infection ^c					
Nosocomial	138 (58.7)	138 (58.7)	1.00	–	–
Community-onset, healthcare-associated	79 (33.6)	51 (21.7)	<0.001	–	–
Community-acquired	18 (7.7)	46 (19.6)	<0.001	–	–
Chronic comorbidities and conditions					
Charlson index, median (IQR)	3 (2–4)	2 (1–4)	0.008	2 (0–3.5)	<0.001
Obesity (Body mass index >30)	35 (15.2)	39 (16.7)	0.61	106 (15.1)	0.98
Diabetes mellitus	70 (29.8)	66 (28.1)	0.66	170 (24.1)	0.083
Chronic pulmonary disease	44 (18.7)	36 (15.3)	0.31	109 (15.5)	0.22
Chronic heart failure (NYHA ≥ 2)	44 (18.7)	28 (11.9)	0.038	84 (11.9)	0.005
Dementia	37 (15.7)	22 (9.4)	0.025	34 (4.8)	<0.001
Hemiplegia	15 (6.4)	9 (3.8)	0.22	14 (2.0)	0.002
Chronic liver disease	15 (6.4)	14 (6.0)	0.83	64 (9.1)	0.63
Chronic renal failure (moderate or severe)	65 (27.7)	33 (14)	<0.001	88 (12.5)	<0.001
Structural disease of the urinary tract	48 (20.4)	40 (17)	0.21	0 (0)	0.001
Connective tissue disease	8 (3.4)	7 (3.0)	0.79	26 (3.7)	0.83
Solid organ cancer	64 (27.2)	57 (24.3)	0.41	143 (20.3)	0.014
Hematologic cancer	12 (5.1)	12 (5.1)	1.00	35 (5.0)	0.90
Bone marrow/stem cell transplantation	1 (0.4)	1 (0.4)	1.00	10 (1.4)	0.17
Neutropenia (<500 cels/μL)	13 (5.8)	8 (3.4)	0.23	27 (3.8)	0.13
Solid organ transplantation	16 (6.8)	13 (5.5)	0.53	28 (4)	0.028
HIV infection	1 (0.4)	2 (0.9)	0.57	14 (2)	0.14
Invasive procedures or therapies					
Central venous catheter (last week)	78 (33.2)	60 (25.5)	0.020	152 (21.6)	<0.001
Urinary catheter (last week)	153 (65.1)	120 (51.1)	0.001	216 (30.6)	<0.001
Mechanical ventilation (last week)	42 (17.9)	45 (19.1)	0.58	96 (13.6)	0.013
Major surgery last month (needing hospital admission)	71 (30.2)	65 (27.7)	0.41	133 (18.9)	<0.001
Endoscopic procedure (last week)	16 (6.8)	18 (7.7)	0.72	30 (4.3)	0.087
Chronic dialysis	23 (9.8)	8 (3.4)	0.008	34 (4.8)	0.001
Immunosuppressive drugs (last 3 months)	59 (25.1)	52 (22.1)	0.40	121 (17.2)	0.002
Exposure to antibacterial agents (last 3 months)					
Any antibiotic received	186 (79.1)	150 (63.8)	<0.001	370 (52.5)	<0.001
Median no. of antibiotics received (IQR)	2 (1–3)	1 (0–2)	<0.001	1 (0–2)	<0.001
Mean days of antibiotics (SD)	18.3 (21.6)	11.2 (17.1)	<0.001	11.0 (23.4)	<0.001

(Table 2 continues on next page)

	CRE group (n = 235) n (%)	CSE group (n = 235) n (%)	p	Non-infected group (n = 705) n (%)	p
(Continued from previous page)					
Carbapenems ^d	33 (14.0)	14 (6.0)	0.010	57 (8.1)	0.004
Mean days of carbapenems ^d (SD)	1.2 (3.5)	0.4 (2.2)	0.011	0.7 (3.3)	0.027
Piperacillin-tazobactam	45 (19.1)	22 (9.4)	<0.001	64 (9.1)	<0.001
Mean days of piperacillin-tazobactam (SD)	1.5 (4.0)	0.7 (2.6)	0.05	0.7 (2.6)	<0.001
Fluoroquinolones ^e	87 (37.0)	56 (23.8)	0.003	146 (20.7)	<0.001
Mean days of fluoroquinolones ^e (SD)	3.2 (5.0)	2.3 (5.4)	0.007	1.9 (5.4)	0.003
Oxymino β-lactams ^f	83 (35.3)	57 (24.3)	0.011	143 (20.3)	<0.001
Mean days of oxymino β-lactams ^f (SD)	3.5 (7.3)	2.0 (4.4)	0.015	1.5 (4.1)	<0.001
Amoxicillin-clavulanic acid or ampicillin-sulbactam	38 (16.2)	36 (15.3)	0.80	65 (9.2)	0.003
Mean days of amoxicillin-clavulanic acid or ampicillin-sulbactam (SD)	1.0 (2.8)	1.4 (4.6)	0.89	0.6 (2.3)	0.024
Aminoglycosides ^g	18 (7.7)	10 (4.2)	0.003	24 (3.4)	0.009
Mean days of aminoglycosides ^g (SD)	0.5 (2.0)	0.2 (1.2)	0.079	0.1 (1.2)	0.023
Broad-spectrum anti-gram negative drugs ^h	164 (69.8)	115 (48.9)	<0.001	277 (39.3)	<0.001
Mean days of broad-spectrum anti-gram negative drugs ^h (SD)	9.4 (10.0)	5.5 (8.2)	<0.001	5.0 (8.8)	<0.001
Antianaerobic drugs ⁱ	106 (45.1)	73 (31.1)	0.001	201 (28.5)	<0.001
Mean days of antianaerobic drugs ⁱ (SD)	5.4 (8.4)	3.4 (6.8)	0.003	3.5 (6.9)	<0.001
Anti-gram positive drugs ^j	39 (16.6)	17 (7.2)	0.001	52 (7.4)	<0.001
Mean days of anti-gram positive drugs ^j (SD)	1.6 (4.6)	0.5 (2.8)	0.008	0.5 (2.6)	<0.001
Time of exposure to broad-spectrum drugs			<0.001		<0.001
No broad spectrum anti-gram negative drugs ^h	70 (29.8)	119 (50.6)		427 (60.6)	
Broad spectrum anti-gram negative drugs ^h <6 days	24 (10.2)	32 (13.6)		52 (7.4)	
Broad spectrum anti-gram negative drugs ^h ≥6 days	141 (60.0)	84 (35.7)		226 (32.1)	
Number of broad-spectrum anti-gram negative drugs			<0.001		<0.001
None	50 (21.3)	96 (40.9)		351 (49.8)	
One	121 (51.5)	112 (47.6)		259 (36.7)	
≥2	64 (27.2)	27 (11.5)		95 (13.5)	

Data are number of patients (percentage) except where specified. CRE: carbapenem-resistant Enterobacterales. CSE: carbapenem-susceptible Enterobacterales. SD: standard deviation. ^aEvidence of any previous positive culture (screening or clinical samples) with isolation of CRE; if no evidence was available (e.g., no previous culture results with CRE), it was considered as no exposure. ^bAs above, for ESBL- or AmpC producing Enterobacterales, carbapenem-resistant *Pseudomonas aeruginosa* or *Acinetobacter baumannii*, methicillin-resistant *Staphylococcus aureus*, or vancomycin-resistant enterococci. ^cNosocomial: infection occurring after 48 h of hospital admission or in <7 days after a previous hospital discharge; community-onset, healthcare-associated infection: those not nosocomially-acquired, in patients with any of the following in the last 3 months: admission to acute or long term-care facility, intravenous therapy, major surgery, specialised home care, renal replacement therapy; community-acquired: all others. ^dErtapenem, meropenem, imipenem. ^eCiprofloxacin, levofloxacin, moxifloxacin, norfloxacin. ^f2nd, 3rd and 4th generation cephalosporins (except cephamycins), and aztreonam. ^gAmikacin, gentamicin, tobramycin. ^hCarbapenems, fluoroquinolones, piperacillin-tazobactam and oxymino-β-lactams. ⁱCarbapenems, β-lactam-β-lactam inhibitors, cephamycins, moxifloxacin, metronidazol, tigecycline, clindamycin. ^jVancomycin, teicoplanin, linezolid, daptomycin. Definitions for other variables are in the study protocol (Annex A).

Table 2: Exposure to the different variables in the three patient-groups

CRE case patients for whom matching controls were found were included in the cases-control-control study. These were matched to 235 CSE controls and 705 non-infected controls. The CRE case patients were recruited in Spain (104), Greece (53), Serbia (36), Turkey (16), Italy (15), Romania (9) and Montenegro (2). The median age of CRE cases was 74 years (IQR, 63–83); 135 (57.4%) were males; 174 (74%) were admitted from home, 148 (63%) were admitted to medical wards, 45 (19.1%) to surgical wards, and 42 (17.9%) to intensive care units (ICU). Their median length of previous stay in hospital was 3 days (IQR 0–14); previous stay was 0–2 days in 113 (48.1%), 3–7 days in 26 (11.1%), 8–14 days in 42 (17.9%), and >14 days in 54 (23.0%).

The type of CRE infection was cUTI in 133 (56.7%), pneumonia in 44 (18.7%), and cIAI and BSI-OR in 29 (12.3%), respectively. *Klebsiella pneumoniae* was the

most frequent pathogen in CRE infections (206; 87.6%), followed by *Enterobacter cloacae* complex (11; 4.6%) and *Escherichia coli* (7; 2.9%); In 7 isolates (2.9%), no carbapenemase genes were found; while in the other 228, carbapenemase genes were coding for either OXA-48 or OXA-48-like enzymes (112 isolates [47.6%]), KPC (84 [35.7%]) or metallo-β-lactamases (MBL) (44 [18.7%]) were found. Interestingly, 13 isolates produced 2 carbapenemases (10 an OXA-48 plus an MBL, and 3 a KPC plus an MBL). Overall, 191 isolates (81.2%) were carbapenem-resistant according to EUCAST breakpoints.

Risk factors for CRE infection in Enterobacterales infection population

The distribution of Enterobacterales isolates was more heterogeneous among patients with CSE infection, with

	CRE vs CSE		CRE vs non-infected	
	Adjusted OR (95% CI)	p	Adjusted OR (95% CI)	p
Intrinsic features				
Age (per year)	–	–	1.03 (1.01–1.05)	0.001
Chronic renal failure (moderate or severe)	2.81 (1.40–5.64)	0.004	–	–
Epidemiological exposures				
Previous colonization/infection by CRE	6.94 (2.74–17.53)	<0.001	13.14 (3.98–43.43)	<0.001
Admission from home	0.44 (0.23–0.85)	0.014	–	–
Previous hospitalization (last 6 months)	–	–	1.84 (0.95–3.55)	0.068
Invasive procedures and therapies				
Urinary catheter (last week)	1.78 (1.03–3.07)	0.038	3.68 (1.86–7.28)	<0.001
Immunosuppressive drugs	–	–	3.38 (1.44–7.93)	0.005
Exposure to antibiotics				
MODEL A: Broad-spectrum anti-gram negative drugs	2.20 (1.25–3.88) ^a	0.006	2.89 (1.45–5.73) ^b	0.002
MODEL B: Days of broad-spectrum anti-gram negative drugs	1.04 (1.00–1.07) ^c	0.014	1.02 (0.99–1.04) ^d	0.081
MODEL C: Time of exposure to broad-spectrum drugs				
No broad spectrum anti-gram negative drugs	Ref ^e	Ref	Ref ^f	Ref
Broad spectrum anti-gram negative drugs, <6 days	1.25 (0.57–2.71)	0.56	3.00 (1.07–8.43)	0.037
Broad spectrum anti-gram negative drugs, ≥6 days	2.86 (1.56–5.26)	0.001	2.96 (1.44–6.06)	0.003
MODEL D: Number of broad-spectrum drugs				
None	Ref ^g		Ref ^h	
One	1.70 (1.00–2.90)	0.050	2.03 (1.23–3.36)	0.006
≥2	3.66 (1.77–7.58)	<0.001	2.95 (1.56–5.60)	<0.001

For exposures of antibiotics, different models were developed: model A included exposure to antibiotic groups as dichotomous variables; model B included duration of exposure to antibiotic groups; model C included only the risk category. Models with individual drugs did not provide significant associations and are not shown. The adjusted data for intrinsic features, epidemiological exposures, and invasive procedures and therapies were obtained for the model A, and were not significantly different for models B and C and therefore are not shown. Previous duration of hospital stay was included in all models. Broad-spectrum anti-gram negative drugs: carbapenems, piperacillin-tazobactam, oxyimino-β-lactams, fluoroquinolones. Reference categories for categorical exposures were “non-exposed” except where specified; for continuous variables (age, days of broad spectrum anti-gram negative drugs), the adjusted OR is per unit. Area under the receiver operating characteristic curve (AUROC) for observed data of the models: ^a0.71 (95% CI: 0.67–0.75). ^b0.81 (95% CI: 0.78–0.84). ^c0.72 (95% CI: 0.68–0.76). ^d0.81 (95% CI: 0.78–0.84). ^e0.73 (95% CI: 0.69–0.77). ^f0.81 (95% CI: 0.78–0.84). ^g0.74 (0.70–0.78). ^h0.81 (0.78–0.84).

Table 3: Multivariate hierarchical conditional logistic regression analysis of risk factors for CRE infection.

age, previous infection/colonisation by CRE, hospitalization in previous six months, use of urinary catheter in the last week, immunosuppressive drugs and use of broad-spectrum anti-gram negative antibiotics. As above, when antibiotics were included as days of exposure (model B), duration of broad-spectrum anti-gram negative drugs was also associated with increased risk, and when the time-categorised variable was included, both <6 and ≥6 days of broad-spectrum anti-gram negative antibiotics were associated with an increased risk for CRE. Also, exposure to ≥2 broad spectrum drugs was associated with higher risk than exposure to one drug. The AUROC of the models were similar with high predictive ability (Table 3).

Subgroups analyses

Subgroup analyses were performed in CRE patients and their matched controls for patients with infections caused by Enterobacterales producing the different carbapenemase-types, for patients with cUTI (as the most frequent type of infection), for community-onset acquisition and for patients without previous evidence of colonisation/infection by CRE.

The results of these subgroups were in general consistent with those of the global analyses, with few exceptions (Table 4). Of note, previous exposure to broad-spectrum anti-gram negative drugs was associated with increased risk in all subgroups but not in the comparison of OXA-producing CRE with CSE nor in patients with community-acquisition of CRE infection against non-infected patients; and surgery was associated with increased risk of CRE among patients who had no evidence of prior colonisation/infection by CRE, and among patients with community acquisition (but only against non-infected patients).

Discussion

In this multinational study, we identified risk factors and patients' profiles for CRE infections. Some specific features of this study include: (a) the multinational participation; (b) the inclusion of infections caused by different mechanisms of carbapenem-resistance; (c) the risk factors were investigated under several specified hypothetical assumptions; (d) the risk factors were

	CRE vs CSE		CRE vs non-infected	
	Adjusted OR (95% CI)	p	Adjusted OR (95% CI)	p
OXA-enzymes producers and matched controls				
Age (per year)	–	–	1.03 (1.00–1.06)	0.010
Chronic renal failure	5.67 (1.58–20.31)	0.008	–	–
Previous hospitalisation	–	–	2.18 (1.23–6.41)	0.013
Admission from home	0.24 (0.08–0.61)	0.005	–	–
Previous colonization/infection by CRE	6.61 (1.83–23.87)	0.004	16.11 (3.38–76.38)	<0.001
Broad-spectrum anti-gram negative drugs	–	–	3.26 (1.40–7.60)	0.006
KPC producers and matched controls				
Age (per year)	–	–	1.04 (1.00–1.09)	0.049
Previous colonization/infection by CRE	13.66 (7.62–71.12)	0.002	7.59 (1.40–41.06)	0.019
Urinary catheter (last week)	3.46 (1.16–10.30)	0.026	–	–
Broad-spectrum anti-gram negative drugs	2.94 (1.09–7.89)	0.032	6.66 (1.71–25.15)	0.005
Metallo-β-lactamase producers and matched controls				
Age (per year)	1.05 (1.00–1.11)	0.002	1.04 (0.99–1.09)	0.064
Solid tumor	15.09 (1.40–161.74)	0.052	–	–
Chronic renal failure	–	–	8.04 (1.32–48.75)	0.023
Broad-spectrum anti-gram negative drugs	15.34 (2.78–84.48)	0.0032	6.07 (1.51–24.42)	0.011
Complicated urinary tract infections and matched controls				
Age (per year)	1.03 (1.00–1.06)	0.029	1.03 (0.99–5.21)	0.052
Chronic renal failure (moderate or severe)	3.24 (1.30–8.11)	0.012	2.25 (0.99–5.12)	0.052
Hemiplegia	3.24 (0.93–11.27)	0.064	–	–
Previous colonization/infection by CRE	14.01 (3.02–65.02)	0.001	16.51 (4.74–57.50)	<0.001
Urinary catheter (last week)	2.10 (1.02–4.31)	0.042	7.95 (3.92–16.12)	<0.001
Broad-spectrum anti-gram negative drugs	2.60 (1.27–5.31)	0.009	2.97 (1.08–5.16)	0.001
Community onset infection (community-acquired and healthcare-associated) and matched controls				
Age (per year)	–	–	1.02 (1.00–1.04)	0.013
Previous hospitalisation	2.58 (1.22–5.48)	0.01	2.00 (1.23–3.27)	0.005
Admission from home	0.28 (0.07–1.04)	0.06	0.47 (0.26–0.87)	0.02
Chronic renal failure	5.73 (1.83–17.90)	0.003	–	–
Dementia	3.38 (1.02–11.20)	0.05	–	–
Previous colonization/infection by CRE	25.50 (2.58–252.0)	0.006	12.80 (4.27–38.50)	<0.001
Urinary catheter (last week)	–	–	2.10 (1.20–3.68)	0.009
Surgery (last month)	–	–	2.14 (1.13–4.05)	0.02
Broad-spectrum anti-gram negative drugs	3.26 (1.30–8.14)	0.01	–	–
Case patients without previous colonisation or infection by CRE and matched controls				
Age (per year)	–	–	1.03 (1.01–1.05)	0.004
Dementia	–	–	3.22 (1.07–9.68)	0.037
Admission from home	0.86 (0.79–0.95)	0.003	–	–
Chronic renal failure (moderate or severe)	3.34 (1.47–7.57)	0.004	2.64 (0.94–7.36)	0.037
Urinary catheter (last week)	1.89 (1.06–3.38)	0.030	2.68 (1.25–5.41)	0.010
Surgery last month	2.18 (1.00–4.75)	0.048	2.38 (0.96–6.18)	0.075
Immunosuppressive drugs	–	–	4.80 (1.83–12.28)	0.001
Broad-spectrum anti-gram negative drugs	2.47 (1.36–4.47)	0.003	4.27 (2.12–8.59)	<0.001

Reference categories for categorical exposures were "non-exposed"; for continuous variables (age, days of broad spectrum anti-gram negative drugs), the adjusted OR is per unit.

Table 4: Multivariate analysis of risk factors for CRE infections in subgroups of patients.

assessed in two populations: patients with Enterobacterales infection and hospital-admitted patients; and (e) a matched design was used to increase the efficiency of the study and ensure the adequate control of the confounding effect of duration of hospitalization and ward of admission, which would otherwise cause an underestimation of the effect of other variables.¹⁶ The

three risk factors that were found in the two populations studied were evidence for previous colonization or infection with CRE, recent use of urinary catheter and recent use of broad spectrum anti-gram negative drugs. Also, we found a higher than expected proportion of patients with non-nosocomial acquisition of the infection and of patients admitted to non-ICU wards.

Regarding the matching variables, it was surprising to see that almost half of the CRE cases had a hospital stay of ≤ 2 days, contradicting the general impression that most of these infections occurred late during hospital admission, confirming some recent observations.¹⁷ Despite most of these patients having had a community-onset but healthcare-associated or a nosocomial infection (after transfer from another hospital), community circulation of CRE might be wider than previously recognised in these areas. However, we cannot reject the possibility that some healthcare-associated infections were misclassified as community-acquired. Also, it is worth noting that only 1/5 of patients were admitted to ICU, highlighting the frequency of infections caused by CRE in conventional wards.

The risk factors identified must be interpreted in the context of the two populations studied. The comparison with patients without infection provides risk estimates for exposures among all admitted patients and the risk factors found may, therefore, be partially generic for Enterobacterales infections and not fully specific for CRE. The comparison with CSE patients provides information useful for empirical therapeutic decisions but might overestimate the effect of some variables selecting for CRE over CSE, mainly exposure to antibiotics.¹⁸ Previous colonisation/infection by CRE, having a urinary catheter and having received broad-spectrum anti-gram negative drugs were associated with CRE in both comparisons, meaning they are truly specific risk factors for CRE infection. Interestingly, the adjusted ORs of previous CRE colonisation/infection and of exposure to broad-spectrum anti-gram negative antibiotics were not higher in the Enterobacterales infection population than in the hospital-admitted patient population, rejecting the hypothesis that their effect would be overestimated in the first population. In contrast, the association with chronic renal failure and being admitted from home (protective) were found in the Enterobacterales infection population only, suggesting that these variables increase risk of a CRE infection over a CSE infection; while older age, previous hospitalisation and immunosuppressive drugs were only found in the hospital-admitted patients-population, suggesting they might be risk factors for Enterobacterales infection in general. Therefore, a better characterization of CRE predictors is gained by comparing the results of both models.

Most previous studies investigating the risk factors for CRE included mostly infections caused by carbapenem-resistant *K. pneumoniae* but no other Enterobacterales species, and the vast majority of studies were performed in a single hospital. A minority of studies provided estimations for both CSE and non-infected control groups and some included matched controls, but overall the designs and methods for controlling the effect of confounders and the variables

studied were very heterogeneous.^{5–8} All these factors jeopardize any comparison of previous estimations with our data. Regarding the bacterial species, some 15% of the CRE cases in our study were caused by bacteria other than *K. pneumoniae*, but their number was insufficient to perform a specific analysis.

The strong association of CRE infection with previous CRE colonization or infection was expected but is nevertheless remarkable. In a recent study performed in high-risk patients (mostly admitted to ICU and haematological wards), all KPC-producing *K. pneumoniae* infections occurred in patients previously colonized.¹⁹ However, this variable was neglected in most previous studies on risk factors^{5–8} because screening is not universally performed and therefore the information is not available for all patients. We decided to explore whether the information regarding previous colonization or infection available in the patients' records in real life would be useful to identify patients at higher risk. Some studies have identified specific risk factors for developing a CRE infection in previously colonized, high-risk patients (again, mostly in ICU), which complement our results.^{20,21} Our study also provides information about risk factors in patients without evidence of previous colonisation.

Contrary to some previous studies,^{5–8} we failed to find associations of specific drugs with increased risk of CRE infection, which might be related to an adequate control of the confounding effect of previous length of stay in our study. Since CRE are typically resistant to most β -lactams and fluoroquinolones, it is reasonable to expect that any broad spectrum drug (and not only carbapenems) would exert a selective pressure once they become endemic in a population. In fact, the antibiotic groups usually considered as the most potent resistant selectors for multidrug-resistant gram negative bacteria (carbapenems, piperacillin-tazobactam, oxyimino- β -lactams and fluoroquinolones²²) were consistently associated with increased risk. We were able to characterise the impact of exposure to these drugs by analysing it as a dichotomous variable (yes/no), as a time-dependent variable and as exposure to one or more of these drugs. We found that >6-day duration of exposure was associated with increased risk, as was exposure to more than one broad-spectrum drug.

Our study had a number of limitations. It may be argued that our study design may have caused an underestimation of the impact of different risk factors due to a potential overmatching effect. However, not matching but adjusting for these variables in the analysis phase bears the risk of time-dependent bias and overestimation of the impact of many other variables,¹⁰ if control patients are selected among very low risk strata of the populations. As a consequence, the risk factors found in our study must be interpreted considering the wards of admission and length of stay for the CRE cases. Our objective was not investigating causal

pathways but providing pragmatic information to help identifying patients at risk and therefore, we did not develop hypothetical direct acyclic graphs for the relation between variables. However, we performed a hierarchical analysis in groups of variables that might act in the same pathway. It should be noted that some variables might act both to facilitate colonization and infection development once colonized (e.g., some comorbidities may favour colonization because of their need of healthcare contact and also infection; also antibiotics may facilitate colonization by eliminating competing flora and infection by selecting resistant bacteria). Other variables might just be proxies for unmeasured variables (e.g., previous hospitalisation and admission from long-term care facilities may be proxies for previous colonisation). The statistical power of the study may have been limited to detect some risk factors. Nevertheless, to the best of our knowledge, this is the biggest study on risk factors for CRE including two types of control patients, and we think the matching criteria used were efficient in identifying real risk factors. As in all case-control studies, the exposures assessment was performed retrospectively. However, the fact that cases and controls were prospectively detected allowed a better identification of exposures. Finally, the results might not be extrapolated to hospitals/areas with a different epidemiology of CRE, or even to participating sites providing low number of cases.

In conclusion, previously detected colonisation/infection by CRE, having a urinary catheter and receiving broad-spectrum anti-gram negative drugs were risk factors for CRE infection among admitted patients matched for ward of admission and length of stay. Other factors to be considered were being admitted from home (protective) and chronic renal failure for patients with Enterobacterales infections, and older age, previous hospitalisation and use of immunosuppressive drugs for hospital-admitted patients. These results might help in endemic areas, both for decisions about using empirical drugs active against CRE in patients, particularly in the case of severe infections, and for better selecting the most patients to be recruited for randomized trials testing drugs against these pathogens.

Contributors

Conceptualisation: Jesús Rodríguez-Baño, Belén Gutiérrez-Gutiérrez, Jose M. Bravo-Ferrer, Tomislav Kostyanov, Marlieke E.A. de Kraker, Jan Feifel, Rafael Cantón, Herman Goossens, Marc J. Bonten. Data curation: Salvador Pérez-Galera, María Paniagua, Jose M. Bravo-Ferrer, Tomislav Kostyanov, Joost Schotsman. Formal analysis: Belén Gutiérrez-Gutiérrez, Salvador Pérez-Galera, Jose M. Bravo-Ferrer, Marlieke de Kraker, Jan Feifel, Jesús Rodríguez-Baño. Funding acquisition: Jesús Rodríguez-Baño, Lionel K. Tan, Herman Goossens, Marc J. Bonten. Investigation: Salvador Pérez-Galera, Jose M. Bravo-Ferrer, María Paniagua, Tomislav Kostyanov, Jesús Sojo-Dorado, Rafael Canton, George L. Daikos, Biljana Carevic, Gorana Dragovac, Lul Raka, Adriana Hristea, Pierluigi Viale, Murat Akova, Jose Maria Reguera, Lucia Valiente de Santis, Julian Torre-Cisneros, Angela Cano, Emmanuel Roilides, Lili Radulovic, Cenk Kirakli, Evelyn Shaw, Matthew E. Falagas, Vicente

Pintado. Methodology: Jesús Rodríguez-Baño, Belén Gutiérrez-Gutiérrez, Jose M. Bravo-Ferrer, Tomislav Kostyanov, Marlieke E.A. de Kraker, Jan Feifel, Rafael Cantón, Herman Goossens, Marc J. Bonten. Project administration: Jose M. Bravo-Ferrer, Lionel Tan, Herman Goossens, Marc J. Bonten, Jesús Rodríguez-Baño. Resources: Rafael Canton, George L. Daikos, Biljana Carevic, Gorana Dragovac, Lul Raka, Adriana Hristea, Pierluigi Viale, Murat Akova, Jose Maria Reguera, Julian Torre-Cisneros, Emmanuel Roilides, Lili Radulovic, Cenk Kirakli, Evelyn Shaw, Matthew E. Falagas, Vicente Pintado, Herman Goossens, Marc J. Bonten, Jesús Rodríguez-Baño. Software: Jose M. Bravo-Ferrer, Joost Schotsman. Supervision: Jesús Rodríguez-Baño, Herman Goossens, Marc J. Bonten. Validation: Jose M. Bravo-Ferrer, Belén Gutiérrez-Gutiérrez, Jesús Rodríguez-Baño. Visualisation: Salvador Pérez-Galera, Jose M. Bravo-Ferrer, María Paniagua, Belén Gutiérrez-Gutiérrez, Jesús Rodríguez-Baño. Writing – original draft: Salvador Pérez-Galera, Jose M. Bravo-Ferrer, Belén Gutiérrez-Gutiérrez, Jesús Rodríguez-Baño. Writing – review & editing: María Paniagua, Tomislav Kostyanov, Marlieke E.A. de Kraker, Jan Feifel, Jesús Sojo-Dorado, Joost Schotsman, Rafael Canton, George L. Daikos, Biljana Carevic, Gorana Dragovac, Lionel K. Tan, Lul Raka, Adriana Hristea, Pierluigi Viale, Murat Akova, Jose Maria Reguera, Lucia Valiente de Santis, Julian Torre-Cisneros, Angela Cano, Emmanuel Roilides, Lili Radulovic, Cenk Kirakli, Evelyn Shaw, Matthew E. Falagas, Vicente Pintado, Herman Goossens, Marc J. Bonten. Salvador Pérez-Galera, Jose M. Bravo-Ferrer, María Paniagua, Marlieke E.A. de Kraker, Jan Feifel, Joost Schotsman, Belén Gutiérrez-Gutiérrez and Jesús Rodríguez-Baño had access to the data. Jose M. Bravo-Ferrer, Belén Gutiérrez-Gutiérrez and Jesús Rodríguez-Baño verified all data. All authors read and approved the final version of the manuscript.

Data sharing statement

Data collected for the study, including de-identified participant data and a data dictionary defining each field in the set, will be made available to other investigators upon request to the corresponding author, after approval of a proposal by the senior authors' institution and the COMBACTE-CARE consortium.

Declaration of interests

George L. Daikos reports personal fees from Pfizer, personal fees from MSD, outside the submitted work. Lionel K. Tan is an employee of and holds stocks and shares in GlaxoSmithKline. Pierluigi Viale reports grants from Shionogi and Gilead; personal fees from Shionogi, MSD, Allianz, Nordic, InfectoPharm, MundiPharm and Angelini, outside the submitted work. Jose Maria Reguera reports non-financial support from Pfizer. Lucia Valiente de Santis reports non-financial support from Pfizer. Julián Torre-Cisneros reports personal fees from MSD, Pfizer, Menarini, and Shionogi; and non-financial support from Pfizer, Shionogi and Gilead, outside the submitted work. Ángela Cano reports personal fees from Shionogi. Emmanuel Roilides reports personal fees from Amplex, Astellas, Gilead, MSD, Pfizer, Scynexis, GSK and Shionogi, outside the submitted work. Marc J. Bonten reports grants paid to his institution from Janssen Vaccines, Novartis, CureVac and Merck; participation in Advisory Boards with payment to his institution from Spherycydes, Pfizer, Merck and Astra-Zeneca, and participation in Data Safety Monitoring Boards with payment to his institution from Sanofi. All other authors have no conflicts to declare.

Acknowledgement

The study was funded by the Innovative Medicines Initiative Joint Undertaking (<https://www.imi.europa.eu/>) under Grant Agreement No. 115620 (COMBACTE-CARE), resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/2007–2013) and EFPIA companies' in kind contribution. S.P.-G., J.M.B.-F., M.P., R.C., J.T.-C., A.C., V.P., B.G.G. and J.R.-B. receives overarching funding for research by Plan Nacional de I+D+I, Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001, RD16/0016/0008, RD16/0016/0011) and CIBERINFEC (21/13/00012, 21/13/00048, 21/13/00084) co-financed by

European Development Regional Fund 'A way to achieve Europe', Operative Program Intelligence Growth 2014–2020.

Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.eclinm.2023.101871>.

References

- WHO. *Antimicrobial resistance: global report on surveillance 2014*. Geneva: World Health Organization; 2014. http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1. Accessed August 26, 2022.
- Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis*. 2018;18:318–327.
- Bartsch SM, McKinnell JA, Mueller LE, et al. Potential economic burden of Carbapenem-Resistant Enterobacteriaceae (CRE) in the United States. *Clin Microbiol Infect*. 2017;23:48.e9–48.e16.
- Wang M, Earley M, Chen L, et al. Clinical outcomes and bacterial characteristics of carbapenem-resistant *Klebsiella pneumoniae* complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. *Lancet Infect Dis*. 2022;22:401–412.
- Hendrik TC, Voor In 't Holt AF, Vos MC. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing *Klebsiella* spp.: a systematic review and meta-analyses. *PLoS One*. 2015;10:e0140754.
- Liu P, Li X, Luo M, et al. Risk factors for carbapenem-resistant *Klebsiella pneumoniae* infection: a meta-analysis. *Microb Drug Resist*. 2018;24:190–198.
- Zhu WM, Yuan Z, Zhou HY. Risk factors for carbapenem-resistant *Klebsiella pneumoniae* infection relative to two types of control patients: a systematic review and meta-analysis. *Antimicrob Resist Infect Control*. 2020;9:23.
- Li J, Li Y, Song N, Chen Y. Risk factors for carbapenem-resistant *Klebsiella pneumoniae* infection: a meta-analysis. *J Glob Antimicrob Resist*. 2020;21:306–313.
- Gutiérrez-Gutiérrez B, Sojo-Dorado J, Bravo-Ferrer J, et al. European prospective cohort study on Enterobacteriaceae showing REsistance to CArbapenems (EURECA): a protocol of a European multicentre observational study. *BMJ Open*. 2017;7:e015365.
- Beyersmann J, Kneib T, Schumacher M, Gastmeier P. Nosocomial infection, length of stay, and time-dependent bias. *Infect Control Hosp Epidemiol*. 2009;30:273–276.
- von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet*. 2007;370:1453–1457.
- Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0, valid from 2022-01-01. European Committee on Antimicrobial Susceptibility Testing. https://www.eucast.org/clinical_breakpoints/. Accessed August 26, 2022.
- Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing *Klebsiella pneumoniae*: differences in therapy and mortality in a multicentre study. *J Antimicrob Chemother*. 2015;70:2133–2143.
- Palacios-Baena ZR, Oteo J, Conejo C, et al. Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain. *J Infect*. 2016;72:152–160.
- Pang D. A relative power table for nested matched case-control studies. *Occup Environ Med*. 1999;56:67–69.
- Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. *Clin Infect Dis*. 2001;32:1055–1061.
- van Duin D, Arias CA, Komarow L, et al. Molecular and clinical epidemiology of carbapenem-resistant Enterobacteriales in the USA (CRACKLE-2): a prospective cohort study. *Lancet Infect Dis*. 2020;20:731–741.
- Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to *Pseudomonas aeruginosa*, *Enterococci*, and *Escherichia coli*. *Clin Infect Dis*. 2002;34:1558–1563.
- Cano Á, Gutiérrez-Gutiérrez B, Machuca I, et al. Association between rectal colonisation by *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae* and mortality: a prospective, observational study. *J Glob Antimicrob Resist*. 2022;29:476–482.
- Giannella M, Trecarichi EM, De Rosa FG, et al. Risk factors for carbapenem-resistant *Klebsiella pneumoniae* bloodstream infection among rectal carriers: a prospective observational multicentre study. *Clin Microbiol Infect*. 2014;20:1357–1362.
- Cano A, Gutiérrez-Gutiérrez B, Machuca I, et al. Risks of infection and mortality among patients colonized with *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*: validation of scores and proposal for management. *Clin Infect Dis*. 2018;66:1204–1210.
- Weiss E, Zahar JR, Lesprit P, et al. Elaboration of a consensual definition of de-escalation allowing a ranking of β -lactams. *Clin Microbiol Infect*. 2015;21:649.e1–649.e10.